PTPN2

Across TCGA pan-cancer cohorts, PTPN2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of PTPN2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where PTPN2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types PTPN2 is over-expressed in tumor.

HNSC, CCRCC, and LSCC are the cancer types where PTPN2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PTPN2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	II,III,IV	+0.726	<.001	12	view →
CCRCC	Female	All	+0.239	<.001	11	view →
LSCC	Male	All	+0.576	<.001	9	view →
LUAD	Male	III,IV	+0.402	<.001	8	view →
PDAC	Female	All	+0.247	.020	1	view →
COAD	All	All	+0.110	.016	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

PTPN2–HNSC

Open the HNSC breakdown →